Document:

EXHIBIT 10.5

                           SECOND EXTENSION AGREEMENT
                          DATED AS OF FEBRUARY 22, 2005
                        BETWEEN DMI BIOSCIENCES, INC. AND
                           COGENCO INTERNATIONAL, INC.

     This Extension Agreement dated as of February 22, 2005 is made by and
between DMI BioSciences, Inc., a Colorado corporation ("DMI") and Cogenco
International, Inc. ("Cogenco"), (collectively referred to as the "Parties").

     WHEREAS, DMI and Cogenco entered into a Term Sheet executed on August 23,
2004 (the "Term Sheet"), requiring, among other things, a standstill period
through November 23, 2004 and the execution of the Co-Development Agreement
referred to below;

     WHEREAS, DMI and Cogenco entered into an Amended Letter of Intent (the
"Amended Letter of Intent") dated and executed on November 5, 2004 (superceding
a previous Letter of Intent dated August 23, 2004) regarding (i) a proposed
Co-Development Agreement relating to the treatment of asthma in humans ("CODA")
and (ii) a proposed subsequent merger and equity investment between the Parties;
and

     WHEREAS, DMI and Cogenco entered into a Co-Development Agreement regarding
the treatment of asthma in humans ("CODA") effective on November 21, 2004
requiring, among other things, a non-refundable $500,000 fee and a
non-refundable $2,500,000 access payment, aggregating $3,000,000, due no later
than November 21, 2004;

     WHEREAS, DMI and Cogenco entered into an Extension Agreement ("Extension
Agreement") effective on January 21, 2005 to extend the time required by Cogenco
to make the non-refundable payments aggregating $3,000,000 to DMI under the CODA
from January 21, 2005 to February 22, 2005, pursuant to Section 8 of the CODA;

     WHEREAS, the Parties mutually desire to extend further the time required by
Cogenco to make the non-refundable payments aggregating $3,000,000 to DMI under
the CODA from February 22, 2005 to July 1, 2005, pursuant to Section 8 of the
CODA;

     NOW THEREFORE, in consideration of the mutual covenants and agreements
contained herein, which the Parties hereto acknowledge and to be good and
sufficient consideration, the Parties hereby agree as follows:

     1. Extension. DMI and Cogenco hereby agree to extend the time Cogenco is
allowed under the CODA and Amended LOI to make certain non-refundable fee and
access payments aggregating $3,000,000 to DMI from February 22, 2005 to July 1,
2005 (the "Second Extension Date"). The CODA and Amended LOI shall remain in
place until the Second Extension Date.

     2. DMI and Cogenco hereby agree to extend the time for the parties to enter
into a merger and equity investment between the Parties as described in
Paragraph 1(b) of the Amended Letter of Intent from March 31, 2005 until
December 31, 2005.

     3. DMI and Cogenco hereby further agree that the date of June 1, 2005
specified in Paragraph 1(d) which provides for the automatic conversion of the
Access Fee payment into One Million (1,000,000) shares of DMI common stock shall
be extended until December 31, 2005.

<PAGE>

     4. Extension Fee. As consideration for the extension granted under this
Second Extension Agreement, Cogenco agrees to increase the non-refundable
$500,000 fee to an aggregate amount of $650,000 which shall be due no later than
July 1, 2005. Therefore, the total non-refundable fee shall be $650,000 and the
non-refundable $2,500,000 access payment in the aggregate amount of $3,150,000
shall be due no later than July 1, 2005;

     4.1 For each $500,000 of the $3,150,000 aggregate payment due under the
CODA that is paid by Cogenco to DMI on or before April 30, 2005, the Extension
Fee will be reduced by $15,000 up to a maximum aggregate reduction of $75,000.

     5. Waiver of Defaults. DMI hereby waives any and all Events of
Noncompliance and Events of Default of whatever nature by Cogenco pursuant to
CODA and Amended LOI until the Extension Date.

     6. Notice. Any notices, papers, demands or communications which are
required to be given in accordance with this Extension Agreement shall be in
writing and shall be delivered to the relevant Parties pursuant to and at the
addresses set forth in Section 24.1 of the CODA.

     7. Miscellaneous. This Extension Agreement may only be amended by the
written agreement of DMI and Cogenco. Unless specified herein, this Extension
Agreement may not be assigned by either party except with the express written
consent of both parties. This agreement shall be binding on DMI and Cogenco and
their successors and assigns. This agreement has been made and executed in the
State of Colorado and shall be construed in accordance with the laws of the
State of Colorado.

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the day and year first above written.

DMI BIOSCIENCES, INC.                         COGENCO INTERNATIONAL, INC.

By:____________________________               By:____________________________
   Bruce G. Miller, President and CEO            David W. Brenman, PresidentEXHIBIT 10.6

       THIRD EXTENSION AGREEMENT AND SECOND AMENDMENT OF LETTER OF INTENT
       DATED AS OF JUNE 7, 2005 BETWEEN DMI BIOSCIENCES, INC. AND COGENCO
                               INTERNATIONAL, INC.

     This Extension Agreement dated as of June 7, 2005 is made by and between
DMI BioSciences, Inc., a Colorado corporation ("DMI") and Cogenco International,
Inc. ("Cogenco"), (collectively referred to as the "Parties").

     WHEREAS, DMI and Cogenco entered into a Term Sheet executed on August 23,
2004 (the "Term Sheet"), requiring, among other things, a standstill period
through November 23, 2004 and the execution of the Co-Development Agreement
referred to below;

     WHEREAS, DMI and Cogenco entered into an Amended Letter of Intent dated and
executed on November 5, 2004 (superceding a previous Letter of Intent dated
August 23, 2004) regarding (i) a proposed Co-Development Agreement relating to
the treatment of asthma in humans ("CODA") and (ii) a proposed subsequent merger
and equity investment between the Parties; and

     WHEREAS, DMI and Cogenco entered into a Co-Development Agreement regarding
the treatment of asthma in humans ("CODA") effective on November 21, 2004
requiring, among other things, a non-refundable $500,000 fee and a
non-refundable $2,500,000 access payment, aggregating $3,000,000, due no later
than November 21, 2004;

     WHEREAS, DMI and Cogenco entered into an Extension Agreement ("Extension
Agreement") effective on January 21, 2005 to extend the time required by Cogenco
to make the non-refundable payments aggregating $3,000,000 to DMI under the CODA
from January 21, 2005 to February 22, 2005, pursuant to Section 8 of the CODA;

     WHEREAS, DMI and Cogenco entered into a Second Extension Agreement ("Second
Extension Agreement") effective on February 22, 2005 to increase the
non-refundable payments to an aggregate $3,150,000 and to extend the time
required by Cogenco to make the non-refundable payments to DMI under the CODA
from February 22, 2005 to July 1, 2005, pursuant to Section 8 of the CODA;

     WHEREAS, on May 13, 2005, Cogenco paid DMI the sum of $1,500,000 reducing
to $1,650,000 the aggregate non-refundable payments due to DMI on or before July
1, 2005, pursuant to Section 8 of the CODA;

     WHEREAS, the Parties mutually desire to extend further the time required by
Cogenco to make the remaining non-refundable payments aggregating $1,650,000 to
DMI under the CODA from July 1, 2005 to September 30, 2005, pursuant to Section
8 of the CODA, and wish to further amend the Amended Letter of Intent dated and
executed on November 5, 2004, to clarify that the provisions of Subsection 1(d)
of the Amended Letter of Intend providing for automatic conversion of the Access
Fee Payment into Shares of DMI Common Stock in the event of Merger/Investment
Failure shall apply pro rate to that portion of the Access Fee Payment actually
made by Cogenco if Cogenco pays less than the entire Access Fee Payment to DMI;

     NOW THEREFORE, in consideration of the mutual covenants and agreements
contained herein, which the Parties hereto acknowledge and to be good and
sufficient consideration, the Parties hereby agree as follows:

<PAGE>

1. Extension. DMI and Cogenco hereby agree to extend the time Cogenco is allowed
under the CODA and Amended LOI to make certain non-refundable fee and access
payments aggregating $1,650,000 to DMI from July 1, 2005 to September 30, 2005
(the "Third Extension Date"). The CODA and Amended LOI shall remain in place
until the Third Extension Date.

2. Pro rate Conversion of Access Fee Payment. DMI and Cogenco hereby agree that
Subsection 1(d) of the Amended Letter of Intent entitled "Special Circumstances
in the event of Merger/Investment Failure" is hereby amended to read as follows:

     "In the event and only in the event that on or before December 31, 2005,
     Cogenco has NOT made an equity investment of between $25-50 million [or
     such other maximum amount mutually agreeable to the parties] into DMI,
     which the parties currently intend will be structured as a tax free section
     368 (A) "reverse triangular merger" ("Merger"), the Access Fee Payment
     provided for in Section 1(a)(i)(3) of the Amended LOI or Section 6.2 of the
     CODA, as amended, shall automatically convert into One Million (1,000,000)
     Shares of DMI Common Stock, no par value. In the event Cogenco has paid
     less than the entire Access Fee Payment, the portion of the Access Fee
     Payment actually made by Cogenco shall automatically convert pro rata into
     Shares of DMI Common Stock, no par value."

3. Waiver of Defaults. DMI hereby waives any and all Events of Noncompliance and
Events of Default of whatever nature by Cogenco pursuant to CODA and Amended LOI
until the Third Extension Date.

4. Notice. Any notices, papers, demands or communications which are required to
be given in accordance with this Third Extension Agreement shall be in writing
and shall be delivered to the relevant Parties pursuant to and at the addresses
set forth in Section 24.1 of the CODA.

5. Miscellaneous. This Third Extension Agreement may only be amended by the
written agreement of DMI and Cogenco. Unless specified herein, this Third
Extension Agreement may not be assigned by either party except with the express
written consent of both parties. This agreement shall be binding on DMI and
Cogenco and their successors and assigns. This agreement has been made and
executed in the State of Colorado and shall be construed in accordance with the
laws of the State of Colorado.

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the day and year first above written.

DMI BIOSCIENCES, INC.                        COGENCO INTERNATIONAL, INC.

By:____________________________               By:____________________________
   Bruce G. Miller, President and CEO            David W. Brenman, President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00086-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00086-of-00352.parquet"}]]